Alkermes reiterates $400M-$420M Q4 proprietary net sales outlook while targeting mid-2027 alixorexton Phase III data

• “On my first quarterly call as CEO of Alkermes, I’d like to start with a few thoughts on the opportunity ahead and the priorities that will guide us… Our focus now is on

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.